Apolipoprotein E genotype and gender influence response to tacrine therapy

Martin Farlow, Debomoy Lahiri, Judes Poirier, Jean Davignon, Siu Hui

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Our objective is to evaluate the effects of apolipoprotein E genotype (APOE) on clinical response to treatment with tacrine, in patients with Alzheimer's disease (AD). Only 25 to 50% of patients with AD, depending on dose and design, have been responders in previous tacrine trials. AD autopsy studies have suggested that APOE ε4 is associated with decreased numbers of cholinergic markers in temporal cortex and the hippocampus. Our hypothesis was that cholinergic therapy might be less effective in ε4 carriers. APOE phenotypes were determined from plasma samples previously saved from a large 30-week, randomized, double-blind placebo-controled, parallel-group, multicenter trial of tacrine at dosages of 80, 120, or 160 mg/day, Outcome measures included Alzheimer's Disease Assessment Scale (ADAS) and its cognitive component (ADAS-Cog), Clinician's Interview-Based Impression (CIBI), Global Deterioration Scale (GDS), and the caregiver-rated Clinical Global Impression of Change (CGIC). Analyses were performed on the change in scores from baseline to last observation on 460 patients having APOE results available, There were 291 patients heterozygous or homozygous for APOE ε4 and 169 patients with only APOE ε2 or ε3 alleles. Analysis of variance showed non-APOE ε4 carriers (E2,3) on tacrine improved more versus placebo than patients with APOE ε4 (E4) on tacrine versus placebo as measured by the ADAS (p = 0.04) and the ADAS-Cog (p = 0.05). A trend toward greater treatment effect in the E2,3 patients was seen with CIBI, GDS, and CGIC, but these differences did not achieve significance. APOE genotype may be a predictor for clinical response to tacrine in AD patients, APOE ε4 associated with a lower probability of cognitive improvement, When the groups were further divided by gender, most of the effect of APOE on treatment response was seen in women. E2-3 women improved more than any other group, and E4 women the least. The interaction of gender and APOE genotype on treatment response as measured by ADAS-Cog was significant (p = 0.03). Future trials of cholinergic therapy in AD should include APOE genotyping.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume802
DOIs
StatePublished - 1996

Fingerprint

Tacrine
Apolipoproteins E
Genotype
Alzheimer Disease
Apolipoprotein E4
Cholinergic Agents
Therapeutics
Deterioration
Placebos
Apolipoprotein E2
Therapy
Apolipoprotein E3
Analysis of variance (ANOVA)
Alzheimer's Disease
Interviews
Temporal Lobe
Plasmas

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Apolipoprotein E genotype and gender influence response to tacrine therapy. / Farlow, Martin; Lahiri, Debomoy; Poirier, Judes; Davignon, Jean; Hui, Siu.

In: Annals of the New York Academy of Sciences, Vol. 802, 1996, p. 101-110.

Research output: Contribution to journalArticle

@article{162027c73c9947a79dc0f4eb3c90f346,
title = "Apolipoprotein E genotype and gender influence response to tacrine therapy",
abstract = "Our objective is to evaluate the effects of apolipoprotein E genotype (APOE) on clinical response to treatment with tacrine, in patients with Alzheimer's disease (AD). Only 25 to 50{\%} of patients with AD, depending on dose and design, have been responders in previous tacrine trials. AD autopsy studies have suggested that APOE ε4 is associated with decreased numbers of cholinergic markers in temporal cortex and the hippocampus. Our hypothesis was that cholinergic therapy might be less effective in ε4 carriers. APOE phenotypes were determined from plasma samples previously saved from a large 30-week, randomized, double-blind placebo-controled, parallel-group, multicenter trial of tacrine at dosages of 80, 120, or 160 mg/day, Outcome measures included Alzheimer's Disease Assessment Scale (ADAS) and its cognitive component (ADAS-Cog), Clinician's Interview-Based Impression (CIBI), Global Deterioration Scale (GDS), and the caregiver-rated Clinical Global Impression of Change (CGIC). Analyses were performed on the change in scores from baseline to last observation on 460 patients having APOE results available, There were 291 patients heterozygous or homozygous for APOE ε4 and 169 patients with only APOE ε2 or ε3 alleles. Analysis of variance showed non-APOE ε4 carriers (E2,3) on tacrine improved more versus placebo than patients with APOE ε4 (E4) on tacrine versus placebo as measured by the ADAS (p = 0.04) and the ADAS-Cog (p = 0.05). A trend toward greater treatment effect in the E2,3 patients was seen with CIBI, GDS, and CGIC, but these differences did not achieve significance. APOE genotype may be a predictor for clinical response to tacrine in AD patients, APOE ε4 associated with a lower probability of cognitive improvement, When the groups were further divided by gender, most of the effect of APOE on treatment response was seen in women. E2-3 women improved more than any other group, and E4 women the least. The interaction of gender and APOE genotype on treatment response as measured by ADAS-Cog was significant (p = 0.03). Future trials of cholinergic therapy in AD should include APOE genotyping.",
author = "Martin Farlow and Debomoy Lahiri and Judes Poirier and Jean Davignon and Siu Hui",
year = "1996",
doi = "10.1111/j.1749-6632.1996.tb32603.x",
language = "English",
volume = "802",
pages = "101--110",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Apolipoprotein E genotype and gender influence response to tacrine therapy

AU - Farlow, Martin

AU - Lahiri, Debomoy

AU - Poirier, Judes

AU - Davignon, Jean

AU - Hui, Siu

PY - 1996

Y1 - 1996

N2 - Our objective is to evaluate the effects of apolipoprotein E genotype (APOE) on clinical response to treatment with tacrine, in patients with Alzheimer's disease (AD). Only 25 to 50% of patients with AD, depending on dose and design, have been responders in previous tacrine trials. AD autopsy studies have suggested that APOE ε4 is associated with decreased numbers of cholinergic markers in temporal cortex and the hippocampus. Our hypothesis was that cholinergic therapy might be less effective in ε4 carriers. APOE phenotypes were determined from plasma samples previously saved from a large 30-week, randomized, double-blind placebo-controled, parallel-group, multicenter trial of tacrine at dosages of 80, 120, or 160 mg/day, Outcome measures included Alzheimer's Disease Assessment Scale (ADAS) and its cognitive component (ADAS-Cog), Clinician's Interview-Based Impression (CIBI), Global Deterioration Scale (GDS), and the caregiver-rated Clinical Global Impression of Change (CGIC). Analyses were performed on the change in scores from baseline to last observation on 460 patients having APOE results available, There were 291 patients heterozygous or homozygous for APOE ε4 and 169 patients with only APOE ε2 or ε3 alleles. Analysis of variance showed non-APOE ε4 carriers (E2,3) on tacrine improved more versus placebo than patients with APOE ε4 (E4) on tacrine versus placebo as measured by the ADAS (p = 0.04) and the ADAS-Cog (p = 0.05). A trend toward greater treatment effect in the E2,3 patients was seen with CIBI, GDS, and CGIC, but these differences did not achieve significance. APOE genotype may be a predictor for clinical response to tacrine in AD patients, APOE ε4 associated with a lower probability of cognitive improvement, When the groups were further divided by gender, most of the effect of APOE on treatment response was seen in women. E2-3 women improved more than any other group, and E4 women the least. The interaction of gender and APOE genotype on treatment response as measured by ADAS-Cog was significant (p = 0.03). Future trials of cholinergic therapy in AD should include APOE genotyping.

AB - Our objective is to evaluate the effects of apolipoprotein E genotype (APOE) on clinical response to treatment with tacrine, in patients with Alzheimer's disease (AD). Only 25 to 50% of patients with AD, depending on dose and design, have been responders in previous tacrine trials. AD autopsy studies have suggested that APOE ε4 is associated with decreased numbers of cholinergic markers in temporal cortex and the hippocampus. Our hypothesis was that cholinergic therapy might be less effective in ε4 carriers. APOE phenotypes were determined from plasma samples previously saved from a large 30-week, randomized, double-blind placebo-controled, parallel-group, multicenter trial of tacrine at dosages of 80, 120, or 160 mg/day, Outcome measures included Alzheimer's Disease Assessment Scale (ADAS) and its cognitive component (ADAS-Cog), Clinician's Interview-Based Impression (CIBI), Global Deterioration Scale (GDS), and the caregiver-rated Clinical Global Impression of Change (CGIC). Analyses were performed on the change in scores from baseline to last observation on 460 patients having APOE results available, There were 291 patients heterozygous or homozygous for APOE ε4 and 169 patients with only APOE ε2 or ε3 alleles. Analysis of variance showed non-APOE ε4 carriers (E2,3) on tacrine improved more versus placebo than patients with APOE ε4 (E4) on tacrine versus placebo as measured by the ADAS (p = 0.04) and the ADAS-Cog (p = 0.05). A trend toward greater treatment effect in the E2,3 patients was seen with CIBI, GDS, and CGIC, but these differences did not achieve significance. APOE genotype may be a predictor for clinical response to tacrine in AD patients, APOE ε4 associated with a lower probability of cognitive improvement, When the groups were further divided by gender, most of the effect of APOE on treatment response was seen in women. E2-3 women improved more than any other group, and E4 women the least. The interaction of gender and APOE genotype on treatment response as measured by ADAS-Cog was significant (p = 0.03). Future trials of cholinergic therapy in AD should include APOE genotyping.

UR - http://www.scopus.com/inward/record.url?scp=0030476825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030476825&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.1996.tb32603.x

DO - 10.1111/j.1749-6632.1996.tb32603.x

M3 - Article

VL - 802

SP - 101

EP - 110

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -